Summary
An open-label, randomized, multi-center study to evaluate the use of Study Drug in the prevention of cancer treatment-related bone loss in post-menopausal women with ER+ and/or PR+ breast cancer receiving letrozole as adjuvant therapy.
Register to download
Meeting Enrollment Goals Breast Cancer
You may also be interested in:
Webcast
THE INSIGHT SERIES: Is there any way to expedite the start-up processes for global non-interventional research? - Part 5
When new drugs are approved, the marketing authorization holders often have to commit themselves to perform additional post-authorization studies.…
View Resource
White Paper
PRA Insights Report 2017 ISPOR-EU Survey Results
As our industry landscape for Real World Research has changed exponentially, our Real World Solutions team performed a short questionnaire at ISPOR…
View Resource
Case Study
Challenging Study Timeline Goals Achieved in Global Post-Authorization Safety Study (PASS)
PRA Health Sciences Late Phase Services is participating in a global real world safety study program, mandated by various regulatory bodies, to…
View Resource
View all related content and resources for Real world solutions
Explore Insights